Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBT: 2019-2024

Historic EBT for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$52.6 million.

  • GeneDx Holdings' EBT rose 11.62% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 102.98%. This contributed to the annual value of -$52.6 million for FY2024, which is 70.21% up from last year.
  • GeneDx Holdings' EBT amounted to -$52.6 million in FY2024, which was up 70.21% from -$176.7 million recorded in FY2023.
  • GeneDx Holdings' 5-year EBT high stood at -$52.6 million for FY2024, and its period low was -$598.0 million during FY2022.
  • For the 3-year period, GeneDx Holdings' EBT averaged around -$275.8 million, with its median value being -$176.7 million (2023).
  • Its EBT has fluctuated over the past 5 years, first tumbled by 712.48% in 2020, then soared by 70.45% in 2023.
  • Yearly analysis of 5 years shows GeneDx Holdings' EBT stood at -$241.3 million in 2020, then declined by 1.68% to -$245.4 million in 2021, then crashed by 143.71% to -$598.0 million in 2022, then spiked by 70.45% to -$176.7 million in 2023, then soared by 70.21% to -$52.6 million in 2024.